Condition: Scleroderma, Diffuse · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| UCLA | Los Angeles, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| UCSF | San Francisco, California, United States | Recruiting |
| Sutter Health Network | San Pablo, California, United States | Recruiting |
| FL Medical Clinic Orlando Health | Zephyrhills, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University Of Iowa | Iowa City, Iowa, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| Michigan Med University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| James Cancer Hospital | Columbus, Ohio, United States | Recruiting |
| Oregon Health Sciences University | Portland, Oregon, United States | Recruiting |
+ 80 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06655896